Eli Lilly and Company $LLY Position Boosted by SevenBridge Financial Group LLC

SevenBridge Financial Group LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 16.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,354 shares of the company’s stock after purchasing an additional 1,162 shares during the period. Eli Lilly and Company comprises 1.1% of SevenBridge Financial Group LLC’s portfolio, making the stock its 21st largest holding. SevenBridge Financial Group LLC’s holdings in Eli Lilly and Company were worth $6,374,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Exencial Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after acquiring an additional 11,396 shares in the last quarter. Rede Wealth LLC purchased a new stake in shares of Eli Lilly and Company during the third quarter worth $487,000. Central Pacific Bank Trust Division raised its holdings in shares of Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after acquiring an additional 1,843 shares in the last quarter. Cidel Asset Management Inc. grew its stake in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after purchasing an additional 5,591 shares in the last quarter. Finally, Oak Family Advisors LLC purchased a new position in Eli Lilly and Company in the third quarter valued at about $1,979,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on LLY shares. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a research note on Thursday, February 5th. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Bank of America dropped their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a report on Monday, December 15th. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Price Performance

NYSE LLY opened at $999.23 on Thursday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock’s 50-day moving average is $1,041.12 and its two-hundred day moving average is $947.08. The firm has a market cap of $944.10 billion, a P/E ratio of 43.54, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will invest $3 billion in China over the next decade to expand supply‑chain and local manufacturing capacity — including production for its oral GLP‑1 orforglipron — which supports global supply resilience and access to China’s large diabetes/obesity market. Eli Lilly to invest $3 billion in China over next decade
• Positive Sentiment: Lilly has filed for approval of its new GLP‑1 treatment in China, a step that could accelerate launches of both injectable and oral therapies in a critical growth market. Eli Lilly plans $3 billion China investment, files for approval of new GLP-1 treatment
• Positive Sentiment: Clinical/program updates: Lilly reported completion of a Phase 1 study for a China program (LY3985863) and continues strong head‑to‑head data for oral orforglipron versus oral semaglutide — supporting market potential for a lower‑cost, high‑volume oral GLP‑1. Eli Lilly Advances New LY3985863 Program With Completion of Phase 1 Study in China
• Positive Sentiment: Access initiatives: Lilly launched Employer Connect to push employer coverage of obesity drugs (discounted pricing and PBM bypass). If widely adopted, this could materially expand payer coverage and volume (potential 2027 upside), though it may compress per‑unit margins. Eli Lilly and Company (LLY) Announces the Launch of its Employer Connect Platform
• Neutral Sentiment: Partnerships and R&D footprint expansion — Lilly is building a Gateway Labs hub with Samsung Biologics in South Korea and pledging regional investments, which support long‑term R&D sourcing and local talent pipelines but won’t drive immediate revenue. Eli Lilly Taps Samsung Biologics To Grow Korean Biotech And Long Term Value
• Neutral Sentiment: Industry movement: a former Lilly communications chief joined Hims & Hers — notable for competitive dynamics around obesity drugs and messaging but not a direct LLY revenue driver. Hims & Hers Hires Ex-Eli Lilly Communications Chief Amid Obesity Drug Strategy Shift
• Negative Sentiment: Payer/regulatory pressure: Lilly warned some Medicare beneficiaries could still face out‑of‑pocket costs above $50 under a new CMS model because certain Part D plans may not fully meet the cap — a potential headwind for uptake and public optics. Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50
• Negative Sentiment: Marketing limits in key markets: India’s regulator warned against direct or surrogate advertising of weight‑loss drugs, which could restrict promotional channels and slow commercial rollout/awareness in a fast‑growing market. India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.